Charlotte Pawlyn

Featured in: Favicon

nature.com Favicon

thelancet.com Favicon

onlinelibrary.wiley.com Favicon

journals.plos.org

Articles

Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm - Blood Cancer Journal

Aug 11, 2024 | nature.com | Charlotte Pawlyn |Fredrik Schjesvold |David Cairns |Maria-Victoria Mateos |Jacob P. Laubach |Katja Weisel | +4 more

AbstractMeasurement of overall survival (OS) remains the gold standard for interpreting the impact of new therapies for multiple myeloma in phase 3 trials. However, as outcomes have improved, it is increasingly challenging to use OS as the primary endpoint if timely approval of novel agents is to be ensured to enable maximum benefit for patients.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →